Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032824085> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W3032824085 abstract "3527 Background: Liquid biopsy is a promising and minimally invasive genetic test examining plasma circulating tumor DNA. Coupled with the rapidly developing next-generation sequencing (NGS) technologies, it holds the potential for implementation in selecting signal-matched therapeutic options. Methods: A retrospective chart review was conducted on adult patients with advanced solid tumors whose tumors were tested with Guardant360 assay, between December 2018 and December 2019. A total of 178 patients were referred for testing by 12 oncologists within a single community cancer center. Results: Referral rates varied widely (2.25% - 22%). The majority of patients (98%) were tested upfront for molecular marker evaluation, in either newly diagnosed advanced cancer patients, or in recurrent patients without enough tissue for testing. Other patients (2%) were evaluated after failure of 1 st line therapy to assess for acquired mutations. A total of 18 histological types were tested, with lung (LCa; n = 90; 50.56%), breast (BCa; n = 31; 17.42%), and colorectal (CRCa; n = 14; 7.87%) cancers being the most common types. In 86.11% of all tests (n = 180), ≥ 1 alteration was detected, while 13.89 % of tests did not reveal any tumor-related mutation, and were considered negative. The average number of alterations per test was 3.1 (±2.14; n = 481), and varied across types: CRCa (4.36), prostate cancer (2.73), BCa (2.97), and LCa (2.59), had the highest average number of alterations per test. Similarly, LCa (48.44%), BCa (19.13%), and CRCa (12.68%), harbored most of the detected somatic alterations (n = 481). Of all the alterations of practical significance (n = 457), TP53 (32.17%), PIK3CA (8.53%), EGFR (7.66%) and KRAS (7.22%), were the most commonly altered genes. Only 1 patient had a positive MSI-H status, amenable to immune-therapy. Of those with positive test results (n = 155), 31 (20%) had ≥ 1 FDA approved, target-matched therapeutic opportunity. Similarly, 71 patients (45.81%) had ≥ 1 target-matched therapeutic opportunity, outside current indications. Lastly, when no FDA-approved target-matched therapy was available (n = 39), results from liquid biopsy testing offered signal-based clinical trial opportunity in 39/39 patients. Conclusions: Implementation of NGS-based liquid biopsy testing is feasible within a community practice. In the era of precision oncology, such assays have the potential to expedite the efforts towards target-matched therapies and signal-based clinical trial opportunities. Further studies are warranted to identify the most-cost effective testing strategies." @default.
- W3032824085 created "2020-06-05" @default.
- W3032824085 creator A5001198370 @default.
- W3032824085 creator A5003121081 @default.
- W3032824085 creator A5006101210 @default.
- W3032824085 creator A5017348700 @default.
- W3032824085 creator A5025434951 @default.
- W3032824085 creator A5028864875 @default.
- W3032824085 creator A5031150005 @default.
- W3032824085 creator A5035683534 @default.
- W3032824085 creator A5038352641 @default.
- W3032824085 creator A5042799869 @default.
- W3032824085 creator A5051439028 @default.
- W3032824085 creator A5061560608 @default.
- W3032824085 creator A5064449830 @default.
- W3032824085 creator A5070745329 @default.
- W3032824085 creator A5082799664 @default.
- W3032824085 date "2020-05-20" @default.
- W3032824085 modified "2023-09-26" @default.
- W3032824085 title "Liquid biopsy: A community-based oncology practice experience." @default.
- W3032824085 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.3527" @default.
- W3032824085 hasPublicationYear "2020" @default.
- W3032824085 type Work @default.
- W3032824085 sameAs 3032824085 @default.
- W3032824085 citedByCount "0" @default.
- W3032824085 crossrefType "journal-article" @default.
- W3032824085 hasAuthorship W3032824085A5001198370 @default.
- W3032824085 hasAuthorship W3032824085A5003121081 @default.
- W3032824085 hasAuthorship W3032824085A5006101210 @default.
- W3032824085 hasAuthorship W3032824085A5017348700 @default.
- W3032824085 hasAuthorship W3032824085A5025434951 @default.
- W3032824085 hasAuthorship W3032824085A5028864875 @default.
- W3032824085 hasAuthorship W3032824085A5031150005 @default.
- W3032824085 hasAuthorship W3032824085A5035683534 @default.
- W3032824085 hasAuthorship W3032824085A5038352641 @default.
- W3032824085 hasAuthorship W3032824085A5042799869 @default.
- W3032824085 hasAuthorship W3032824085A5051439028 @default.
- W3032824085 hasAuthorship W3032824085A5061560608 @default.
- W3032824085 hasAuthorship W3032824085A5064449830 @default.
- W3032824085 hasAuthorship W3032824085A5070745329 @default.
- W3032824085 hasAuthorship W3032824085A5082799664 @default.
- W3032824085 hasConcept C121608353 @default.
- W3032824085 hasConcept C126322002 @default.
- W3032824085 hasConcept C143998085 @default.
- W3032824085 hasConcept C2775934546 @default.
- W3032824085 hasConcept C2776135927 @default.
- W3032824085 hasConcept C2780192828 @default.
- W3032824085 hasConcept C512399662 @default.
- W3032824085 hasConcept C526805850 @default.
- W3032824085 hasConcept C71924100 @default.
- W3032824085 hasConcept C90924648 @default.
- W3032824085 hasConceptScore W3032824085C121608353 @default.
- W3032824085 hasConceptScore W3032824085C126322002 @default.
- W3032824085 hasConceptScore W3032824085C143998085 @default.
- W3032824085 hasConceptScore W3032824085C2775934546 @default.
- W3032824085 hasConceptScore W3032824085C2776135927 @default.
- W3032824085 hasConceptScore W3032824085C2780192828 @default.
- W3032824085 hasConceptScore W3032824085C512399662 @default.
- W3032824085 hasConceptScore W3032824085C526805850 @default.
- W3032824085 hasConceptScore W3032824085C71924100 @default.
- W3032824085 hasConceptScore W3032824085C90924648 @default.
- W3032824085 hasLocation W30328240851 @default.
- W3032824085 hasOpenAccess W3032824085 @default.
- W3032824085 hasPrimaryLocation W30328240851 @default.
- W3032824085 hasRelatedWork W12100952 @default.
- W3032824085 hasRelatedWork W17456534 @default.
- W3032824085 hasRelatedWork W18079989 @default.
- W3032824085 hasRelatedWork W3087432 @default.
- W3032824085 hasRelatedWork W3761074 @default.
- W3032824085 hasRelatedWork W5608413 @default.
- W3032824085 hasRelatedWork W6423048 @default.
- W3032824085 hasRelatedWork W6897702 @default.
- W3032824085 hasRelatedWork W8428010 @default.
- W3032824085 hasRelatedWork W7988773 @default.
- W3032824085 isParatext "false" @default.
- W3032824085 isRetracted "false" @default.
- W3032824085 magId "3032824085" @default.
- W3032824085 workType "article" @default.